What the buyer needs
AI summaryARPA-H seeks proposals from early career investigators and their organizations for cutting-edge biomedical, health, and community-engaged research and innovation. This solicitation anticipates multiple Other Transaction awards. Amendment 1 clarifies submission limits and updates forms and FAQs. Amendment 2 provides question and answer documents for interested parties. The initiative focuses on identifying and engaging early career researchers.
Incumbent and award research
No incumbent history found for this requirement. The notice does not cite a current contract, and no earlier award from this buying office matches it.
Market context
Awards in the same category (Research and Development in Biotechnology (except Nanobiotechnology)). This is not this requirement's award history.
Recent similar awards: Department of Health and Human Services, NAICS 541714, performed in DC
| Vendor and award | Value | Ends |
|---|---|---|
| ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)75A50123C00010 · THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE | $163.1M | Sep 30, 2030 |
| MELINTA THERAPEUTICS, LLC75A50123C00022 · ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TRE | $47.5M | Jun 30, 2030 |
| ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)75A50119C00055 · THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBU | $145.4M | Sep 30, 2027 |
| BATTELLE MEMORIAL INSTITUTE75A50125F61004 · USE OF A HUMAN-RELEVANT SMALL ANIMAL MODEL OF SULFUR MUSTARD (SM)-INDUCED INHALATION INJUR | $7.6M | Mar 28, 2027 |
| INFLO MEDICAL INC75A50124C00019 · THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO IMPROVE THE SAFETY METRICS FOR EXTRACORPOREAL | $747.4K | Jun 21, 2026 |
Top vendors in this category: Department of Health and Human Services, NAICS 541714, since Oct 1, 2024
1,152 contract awards in this NAICS over the period.
- 1. ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)$336.6M
- 2. AMGEN USA INC$215.9M
- 3. START2 GROUP, INC.$194.3M
- 4. SHIONOGI INC$156.1M
- 5. MAPP BIOPHARMACEUTICAL, INC.$133.1M
Source: USAspending.gov federal award data (U.S. federal public data). A contract is called the incumbent only when the notice or its documents cite it by number.